PolyPid (PYPD) Lytham Partners Fall 2026 Investor Conference summary

Technology and product overview

• Kynatrix platform enables long-acting, controlled drug release using a unique polymer-lipid matrix for customizable applications, initially targeting surgical site infections.

• Over 170 patents granted, with a pipeline leveraging the platform for various APIs and indications.

• Lead product combines doxycycline with the platform, providing 30-day incision coverage to meet CDC infection criteria.

Clinical data and efficacy

• Phase III global study with 1,000 patients showed a 40% reduction in infection, mortality, and reoperation rates compared to standard care.

• Surgical site infection rates dropped from 10% to 4% in open colorectal surgery, outperforming minimally invasive benchmarks.

• Statistically significant results with P values well below FDA thresholds for approval.

Market opportunity and commercialization

• Addressable U.S. market includes 12 million procedures, with 4 million abdominal surgeries annually.

• Strategic partnership with Azurity Pharmaceuticals grants them U.S. and Canada commercialization rights, while manufacturing and other territories are retained.

• Azurity will fund label expansion into additional surgeries with high unmet needs, such as orthopedic and breast procedures.